Cellyan Biotechnology Co. Ltd Class A Ordinary Shares (HKPD)

FairStock Score: 42/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses I can understand, run by able people, at a price that leaves room for error. Cellyan is an OTC pharmaceutical distributor and logistics provider in Hong Kong and Mainland China, with only 11 employees and a market value of $15.7M at the 2026-10-13 close of $0.10. The business is understandable enough, but the numbers do not yet show quality: FairStock's calculated P/E is -1.50, P/B is 0.26, ROE is -15.59%, ROCE is -5.64%, and the Piotroski F-Score is 2/9. That combination says the company is losing money and has weak financial momentum. The low debt-to-equity of 0.13 and Altman Z-Score of 3.79 are reassuring on solvency, but they do not create a moat. Cross-border OTC distribution sounds competitive, and without scale, pricing power is doubtful. The stock has fallen from a 52-week high of $1.72 to $0.10, so the market has already marked it down severely. A P/B of 0.26 might look cheap, but if returns are negative, book value can shrink. With only zero years of filed results, no Lynch category can be assigned, and I have no multi-year record to judge management or growth. This may be a statistical bargain, but Graham warned that cheap-looking assets can be traps without earnings power. I would need evidence of durable profits, stable book value, and a real competitive advantage before calling it a sound value investment.

In plain English: Cellyan Biotechnology is a small company that buys and distributes over-the-counter medicines and provides logistics and e-commerce supply-chain services in Hong Kong and mainland China. The business looks weak today: it is losing money, has a very short public record, and the stock has collapsed over the past year. The price is low compared with its accounting value, but that discount may not be a true bargain if losses continue.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer